论文部分内容阅读
目的 研究卵巢癌组织中 p2 1表达及其预后意义。方法 采用免疫组化检测 75例卵巢癌组织中 p2 1、p5 3表达情况 ,结合临床病理因素探讨 p2 1表达与卵巢癌预后的关系。结果 (1) p2 1与 p5 3表达与不相关 (P=0 .197) ;(2 )p2 1高表达率为 6 1.33% (46 /75 ) ,它与年龄、腹水、FIGO分期、病理类型、分化程度、残瘤大小、初复治等临床病理因素不相关 ;(3)多因素分析表明残留大小 (P=0 .0 316 )、p2 1表达 (P=0 .0 172 )、FIGO分期 (P=0 .0 198)是独立的危险因素。尤其在初治病例中 ,p2 1高表达者预后差。结论 p2 1表达可作为卵巢癌初治患者新的预后指标而指导临床治疗
Objective To study the expression of p21 in ovarian cancer and its prognostic significance. Methods Immunohistochemistry was used to detect the expression of p21 and p53 in 75 cases of ovarian cancer. The relationship between the expression of p21 and the prognosis of ovarian cancer was analyzed by clinicopathological factors. Results (1) The expressions of p21 and p53 were not correlated (P = 0.197). (2) The high expression rate of p21 was 6 1.33% (46/75), which was correlated with age, ascites, FIGO stage, pathological type (3) Multiple factor analysis showed that the residual size (P = 0.016), p21 expression (P = 0.0172), FIGO staging (P = .0198) were independent risk factors. Especially in the initial treatment cases, p21 high expression of poor prognosis. Conclusion p21 expression can be used as a new prognostic indicator of ovarian cancer patients to guide the clinical treatment